Sunitinib

Sunitinib Reactions 1704, p349 - 2 Jun 2018 Hypothyroidism and thyrotoxicosis: 4 case reports In a retrospective study of 29 patients, 4 patients [ages and sexes not stated] were described, who developed hypothyroidism during treatment with sunitinib for metastatic renal cell carcinoma. Of the four patients, one patient also developed and thyrotoxicosis during treatment with sunitinib [routes, dosages and time to reaction onsets and outcomes not stated]. Patient 1: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed hypothyroidism. The patient underwent total thyroidectomy. A pathology exam performed after total thyroidectomy showed diffuse sclerosing variant of papillary thyroid carcinoma. Patient 2: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed hypothyroidism. The pathology exam showed a 30 /18 mm thyroid nodule. The patient was awaiting thyroid surgery. Patient 3: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed hypothyroidism. The patient refused fine needle biopsy aspiration and cytology exam. Patient 4: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed recurrent episodes of transient destructive thyrotoxicosis, which was proved by reduced iodine 131 [131 I radio-iodine] uptake at 2 and 24 hours and significant elevation of serum thyroglobulin levels at 300 ng/mL. The patient developed an episode of sub-clinical hypothyroidism between the episodes of thyrotoxicosis. Finally, the patient developed persistent overt hypothyroidism, which required levothyroxine therapy. Author comment: "In our series, we reported only patients with sunitinib-induced thyroid dysfunction." Trifanescu R-A, et al. Sunitinib, a vegfr receptor tyrosine kinase inhibitor and its thyroid effects. Farmacia (Bucharest) 66: 331-336, No. 2, 2018 - Romania 803323410 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Sunitinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/sunitinib-ZTB3MOO5Xt
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46992-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p349 - 2 Jun 2018 Hypothyroidism and thyrotoxicosis: 4 case reports In a retrospective study of 29 patients, 4 patients [ages and sexes not stated] were described, who developed hypothyroidism during treatment with sunitinib for metastatic renal cell carcinoma. Of the four patients, one patient also developed and thyrotoxicosis during treatment with sunitinib [routes, dosages and time to reaction onsets and outcomes not stated]. Patient 1: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed hypothyroidism. The patient underwent total thyroidectomy. A pathology exam performed after total thyroidectomy showed diffuse sclerosing variant of papillary thyroid carcinoma. Patient 2: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed hypothyroidism. The pathology exam showed a 30 /18 mm thyroid nodule. The patient was awaiting thyroid surgery. Patient 3: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed hypothyroidism. The patient refused fine needle biopsy aspiration and cytology exam. Patient 4: The patient, who had metastatic renal cell carcinoma, started receiving treatment with sunitinib 4 weeks on and 2 weeks off regimen. Subsequently, the patient developed recurrent episodes of transient destructive thyrotoxicosis, which was proved by reduced iodine 131 [131 I radio-iodine] uptake at 2 and 24 hours and significant elevation of serum thyroglobulin levels at 300 ng/mL. The patient developed an episode of sub-clinical hypothyroidism between the episodes of thyrotoxicosis. Finally, the patient developed persistent overt hypothyroidism, which required levothyroxine therapy. Author comment: "In our series, we reported only patients with sunitinib-induced thyroid dysfunction." Trifanescu R-A, et al. Sunitinib, a vegfr receptor tyrosine kinase inhibitor and its thyroid effects. Farmacia (Bucharest) 66: 331-336, No. 2, 2018 - Romania 803323410 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off